Multiplicities in Cancer Research: Ubiquitous and Necessary Evils

被引:28
作者
Berry, Donald [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
关键词
NEGATIVE BREAST-CANCER; ADJUVANT CHEMOTHERAPY; MULTIPLE COMPARISONS; RESPONSIVENESS; THERAPY; ERBB-2; HER2;
D O I
10.1093/jnci/djs301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Scientific inquiry involves observations and measurements, some of which are planned and some of which are not. The most interesting or unusual observations might be regarded as discoveries and therefore particularly worthy of publication. However, the observational process is fraught with inferential land mines, especially if the discoveries are serendipitous. Multiple observations increase the probability of false-positive conclusions and have led to many false and otherwise misleading publications. Statisticians recommend adjustments to final inferences with the goal of reducing the rate of false positives, a strategy that increases the rate of false negatives. Some scientists object to making such adjustments, arguing that it should not be more difficult to determine the validity of a discovery simply because other observations were made. Which tack is right? How does one decide that any particular scientific discovery is real? Unfortunately, there is no panacea, no one-size-fits-all approach. The goal of this commentary is to elucidate the issues and provide recommendations for conducting and reporting results of empirical studies, with emphasis on the problems of multiple comparisons and other types of multiplicities, including what I call "silent multiplicities." Because of the many observations, outcomes, subsets, treatments, etc, that are typically made or addressed in epidemiology and biomarker research, these recommendations may be particularly relevant for such studies. However, the lessons apply quite generally. I consider both frequentist and Bayesian statistical approaches.
引用
收藏
页码:1124 / 1132
页数:9
相关论文
共 29 条
[1]  
[Anonymous], CANC SCI MANY DISCOV
[2]  
[Anonymous], 2010, New YorkerDecember 13
[3]  
Baggerly KA, 2011, AMSTAT NEWS, V403, P16
[4]   Raise standards for preclinical cancer research [J].
Begley, C. Glenn ;
Ellis, Lee M. .
NATURE, 2012, 483 (7391) :531-533
[5]  
BERGER JO, 1988, AM SCI, V76, P159
[6]  
Berry D.A., 1988, BAYESIAN STAT 3, P79
[7]   Bayesian perspectives on multiple comparisons [J].
Berry, DA ;
Hochberg, Y .
JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1999, 82 (1-2) :215-227
[8]  
Berry DA., 1996, STAT BAYESIAN PERSPE
[9]  
Berry DA, 1995, BAYESIAN STAT, V5, P45
[10]   The difficult and ubiquitous problems of multiplicities [J].
Berry, Donald A. .
PHARMACEUTICAL STATISTICS, 2007, 6 (03) :155-160